Related Experiment Video
Updated: Feb 15, 2026

Single-step Purification of Macromolecular Complexes Using RNA Attached to Biotin and a Photo-cleavable Linker
Published on: January 3, 2019
ADME and Safety Aspects of Non-cleavable Linkers in Drug Discovery and Development
M Walles1, A Connor1, D Hainzl1
1Novartis Institute for Biomedical Research, 250 Massachusetts Ave, 1B-123, Cambridge, MA, United States.
Abstract:
Non-cleavable linkers are used in a number of different modalities for various reasons, such as linking an active drug moiety to half-life extending molecules, to groups that enable a specific tissue or cell targeting or to facilitate active uptake into target cells. Non-cleavable linkers do not have a designated weak point in their structure that can lead to cleavage by proteases, hydrolases or chemically by pH changes. Consequently, when designing a conjugate, the choice of a non-cleavable over a cleavable linker is usually a consequence of pursuing a certain mode of action where the stability of the complex is more important than a fast liberation of the active moiety. Linkers of various length, polarity, stability and flexibility are used for different types of conjugates and the linker design is mostly driven by the particular purpose and desired mode of action. This article reviews non-cleavable linkers applied predominantly in Antibody Drug Conjugates (ADCs), and how they influence these conjugates in terms of ADME properties (absorption, distribution, metabolism and elimination) and safety.
Related Concept Videos
Drug Discovery: Overview
Quantitative Aspects of Drug-Receptor Interaction
Survey Safety
Cytoskeletal Linker Proteins - Plakins
Household Wiring And Electrical Safety
In Vitro Drug Release Testing: Overview, Development and Validation

